LUNG PE Ratio & Valuation,Is LUNG Overvalued

LUNG Relative Valuation

LUNG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LUNG is overvalued; if below, it's undervalued.

Historical Valuation

Pulmonx Corp (LUNG) is now in the Fair zone, suggesting that its current forward PS ratio of 1.15 is considered Fairly compared with the five-year average of -12.01. The fair price of Pulmonx Corp (LUNG) is between 2.40 to 5.71 according to relative valuation methord.

Relative Value

Fair Zone

2.40-5.71

Current Price：2.53

Fair

-1.82

-1.66

EV/EBITDA

Pulmonx Corp. (LUNG) has a current EV/EBITDA of -1.66. The 5-year average EV/EBITDA is -12.21. The thresholds are as follows: Strongly Undervalued below -40.79, Undervalued between -40.79 and -26.50, Fairly Valued between 2.07 and -26.50, Overvalued between 2.07 and 16.36, and Strongly Overvalued above 16.36. The current Forward EV/EBITDA of -1.66 falls within the Historic Trend Line -Fairly Valued range.

-1.46

EV/EBIT

Pulmonx Corp. (LUNG) has a current EV/EBIT of -1.46. The 5-year average EV/EBIT is -10.54. The thresholds are as follows: Strongly Undervalued below -34.91, Undervalued between -34.91 and -22.73, Fairly Valued between 1.65 and -22.73, Overvalued between 1.65 and 13.84, and Strongly Overvalued above 13.84. The current Forward EV/EBIT of -1.46 falls within the Historic Trend Line -Fairly Valued range.

1.15

Pulmonx Corp. (LUNG) has a current PS of 1.15. The 5-year average PS is 10.66. The thresholds are as follows: Strongly Undervalued below -11.90, Undervalued between -11.90 and -0.62, Fairly Valued between 21.94 and -0.62, Overvalued between 21.94 and 33.22, and Strongly Overvalued above 33.22. The current Forward PS of 1.15 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Pulmonx Corp. (LUNG) has a current P/OCF of 0.00. The 5-year average P/OCF is -7.53. The thresholds are as follows: Strongly Undervalued below -37.35, Undervalued between -37.35 and -22.44, Fairly Valued between 7.38 and -22.44, Overvalued between 7.38 and 22.29, and Strongly Overvalued above 22.29. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.84

P/FCF

Pulmonx Corp. (LUNG) has a current P/FCF of -3.84. The 5-year average P/FCF is -10.62. The thresholds are as follows: Strongly Undervalued below -35.46, Undervalued between -35.46 and -23.04, Fairly Valued between 1.80 and -23.04, Overvalued between 1.80 and 14.22, and Strongly Overvalued above 14.22. The current Forward P/FCF of -3.84 falls within the Historic Trend Line -Fairly Valued range.

Pulmonx Corp (LUNG) has a current Price-to-Book (P/B) ratio of 1.75. Compared to its 3-year average P/B ratio of 2.65 , the current P/B ratio is approximately -34.17% higher. Relative to its 5-year average P/B ratio of 3.83, the current P/B ratio is about -54.42% higher. Pulmonx Corp (LUNG) has a Forward Free Cash Flow (FCF) yield of approximately -31.21%. Compared to its 3-year average FCF yield of -17.16%, the current FCF yield is approximately 81.89% lower. Relative to its 5-year average FCF yield of -12.33% , the current FCF yield is about 153.07% lower.

1.75

P/B

Median3y

2.65

Median5y

3.83

-31.21

FCF Yield

Median3y

-17.16

Median5y

-12.33

Competitors Valuation Multiple

The average P/S ratio for LUNG's competitors is 1.03, providing a benchmark for relative valuation. Pulmonx Corp Corp (LUNG) exhibits a P/S ratio of 1.15, which is 11.8% above the industry average. Given its robust revenue growth of 5.47%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of LUNG decreased by 62.74% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 20.39M to 21.50M.

The secondary factor is the Margin Expansion, contributed -6.44%to the performance.

Overall, the performance of LUNG in the past 1 year is driven by Revenue Growth. Which is more sustainable.

5.47%

20.39M → 21.50M

Revenue Growth

-6.44%

-69.38 → -64.91

Margin Expansion

-61.77%

-4.71 → -1.80

P/E Change

-62.74%

6.79 → 2.53

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Pulmonx Corp (LUNG) currently overvalued or undervalued?

What is Pulmonx Corp (LUNG) fair value?

LUNG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Pulmonx Corp (LUNG) is between 2.40 to 5.71 according to relative valuation methord.

How does LUNG's valuation metrics compare to the industry average?

The average P/S ratio for LUNG's competitors is 1.03, providing a benchmark for relative valuation. Pulmonx Corp Corp (LUNG) exhibits a P/S ratio of 1.15, which is 11.80% above the industry average. Given its robust revenue growth of 5.47%, this premium appears unsustainable.

What is the current P/B ratio for Pulmonx Corp (LUNG) as of Dec 15 2025?

As of Dec 15 2025, Pulmonx Corp (LUNG) has a P/B ratio of 1.75. This indicates that the market values LUNG at 1.75 times its book value.

What is the current FCF Yield for Pulmonx Corp (LUNG) as of Dec 15 2025?

As of Dec 15 2025, Pulmonx Corp (LUNG) has a FCF Yield of -31.21%. This means that for every dollar of Pulmonx Corp’s market capitalization, the company generates -31.21 cents in free cash flow.

What is the current Forward P/E ratio for Pulmonx Corp (LUNG) as of Dec 15 2025?

As of Dec 15 2025, Pulmonx Corp (LUNG) has a Forward P/E ratio of -1.82. This means the market is willing to pay $-1.82 for every dollar of Pulmonx Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Pulmonx Corp (LUNG) as of Dec 15 2025?

As of Dec 15 2025, Pulmonx Corp (LUNG) has a Forward P/S ratio of 1.15. This means the market is valuing LUNG at $1.15 for every dollar of expected revenue over the next 12 months.

LUNG Valuation